Drug Profile

RT 110

Alternative Names: RT-110 - Rani Therapeutics; RT110

Latest Information Update: 28 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Rani Therapeutics
Class Hormones
Mechanism of Action Parathyroid hormone replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Suspended Hypoparathyroidism

Most Recent Events

20 Mar 2024 Suspended - Preclinical for Hypoparathyroidism in USA (PO)
21 Nov 2022 Rani Therapeutics has patent protection for RaniPill™ capsule technology (Rani Therapeutics website, November 2022)
10 Nov 2022 Rani Therapeutics plans a phase I trial for Hypoparathyroidism in 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com